RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
about
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cellsSelumetinib-enhanced radioiodine uptake in advanced thyroid cancerEffects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid CancerOncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.RET gene abnormalities and thyroid disease: who should be screened and whenMicrosomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.The role of podoplanin in the biology of differentiated thyroid cancers.Thyroid cancer: current molecular perspectives.The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancerMulti-targeted approach in the treatment of thyroid cancer.MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivoThyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.KT5823 differentially modulates sodium iodide symporter expression, activity, and glycosylation between thyroid and breast cancer cells.RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.Modulation of sodium iodide symporter in thyroid cancerIdentification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoproteinIntracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.Drosophila Cancer Models Identify Functional Differences between Ret Fusions.Oxidoreductase interactions include a role for ERp72 engagement with mutant thyroglobulin from the rdw/rdw rat dwarf.Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cellsThyroid carcinoma: molecular pathways and therapeutic targetsThe beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.Single photon emission computed tomography imaging for temporal dynamics of thyroidal and salivary radionuclide accumulation in 17-allyamino-17-demothoxygeldanamycin-treated thyroid cancer mouse model.Clinicopathologic and molecular disease prognostication for papillary thyroid cancer.Clinical implications of molecular markers in follicular cell-derived thyroid cancer.Teaching an old dogma new tricks: twenty years of Shc adaptor signalling.Signaling adaptor ShcD suppresses extracellular signal-regulated kinase (Erk) phosphorylation distal to the Ret and Trk neurotrophic receptors.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.Somatostatin activates Ras and ERK1/2 via a G protein βγ-subunit-initiated pathway in thyroid cells.Ras oncoprotein disrupts the TSH/CREB signaling upstream adenylyl cyclase in human thyroid cell.mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines.Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.Genetics of papillary thyroid cancer initiation: implications for therapyNew targeted molecular therapies for dedifferentiated thyroid cancer.Candidate agents for papillary thyroid cancer identified by gene expression analysis.An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma.
P2860
Q24519206-6421ED61-F86D-48C5-A699-8FBF2F679E43Q24596266-DCE7B1FB-37C7-42F0-AF32-D3F72923432EQ24652758-44E623C7-876A-418D-84BE-7892AD71F115Q27824825-C2C45D53-EEC1-4BB6-948D-6CBFE2693C16Q28709562-7FB23412-2370-4188-A79A-DC8ABF3F2D15Q33193878-F36C6D67-8E67-4614-8C49-2E451367C043Q33568168-870C11BB-1CEC-49BB-82DC-2FE97094B441Q33760910-7D6CED7A-F908-4FEB-8C8B-0FE780DFEC0AQ33770842-76C941A6-1DA2-4A11-A08C-E321F1931446Q33982413-86AE0923-EBEC-4A60-A4FC-E5826C72A9C5Q34109756-CA75A3A0-23C0-4E08-BFBE-20EBB0B85256Q34533804-7E11EDC4-7370-4386-83FD-0AB05A02536DQ34578515-40B571C9-B7F2-485B-88DC-5349B41ED3EAQ35124840-E2090C2C-30F8-47BE-B097-AF5826EA750BQ35437491-C5D5663E-93F4-4253-8FEA-63EE0C04BB94Q35578577-4BEA6F2D-9064-4916-A6EB-1D875C4FBF3AQ35690173-60D9D15B-1785-4ED1-829C-71AC2813A27BQ35763320-04513BF8-1DE9-49D8-9A38-7D1F3E524F13Q35977327-DB3777B5-DEAB-45C4-B233-BA679A41D051Q36132331-3D0E4749-68C6-4E4C-BB5A-B800B39B6111Q36890014-FB4DCAC5-718A-4210-A81E-41B1E11E276FQ37035285-77C42D07-1A10-43DC-B17F-2E00530282DDQ37035505-91DCC3FF-6C4A-4A18-BD9D-B7C8E3B4628DQ37078783-3C39B6B5-1B58-4C53-A7B2-DC1A2EF17852Q37147768-74A0F434-B4F4-4403-BF31-D7264029D9FDQ37351482-E6798B47-D4CC-42F3-BFD1-C8350C66DE23Q37518427-C1DAB7F9-8150-432D-9929-191F56DC5390Q37598938-3445BD71-100F-4E00-B379-E8B883B083B3Q37611825-C2D55AED-43B4-41E1-AEB8-0C24CA88DF4EQ38042699-FDFABF42-2B0C-4E39-B6DE-6E29AF3241DDQ38715948-26DF1F0D-004B-4FA7-8033-6BF425E900C4Q38823954-1F2FF76A-E700-4E95-A4F3-A2EDE8EA1CE0Q38827518-194E8A3D-D20B-40F3-8114-E5594B5DF712Q38995868-2C2E3492-C47C-4EA9-B1A9-210C9BC25B4DQ39006509-7130A456-AB7D-4EFE-8EB2-F5AFC2D7723FQ39350519-A9E81C82-2131-4B45-9CF8-26FAC90306F5Q41908055-0F29F95F-AF49-42FF-BEED-BAD94C0462F2Q42734670-4DE06D03-8C01-4AA5-AE11-1F8FD44905B5Q43548418-B33ECC2F-6EF1-4641-BCBA-414F84C68AE8Q44116793-18F02B46-0233-4CAE-82B8-AD9826E2A7BD
P2860
RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.
@en
RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.
@nl
type
label
RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.
@en
RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.
@nl
prefLabel
RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.
@en
RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.
@nl
P2093
P2860
P356
P1433
P1476
RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.
@en
P2093
Hiroaki Kuroda
James A Fagin
Jeffrey A Knauf
Saswata Basu
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206602
P407
P577
2003-07-01T00:00:00Z
P5875
P6179
1018892721